REGENERON PHARMACEUTICALS, INC.

REGN · CIK 0000872589

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$14.34B1.0%

FY2025

Net income (FY)

$4.50B2.1%

FY2025

Free cash flow (FY)

$4.08B11.3%

FY2025

Diluted EPS (FY)

$41.488.2%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 60.1× since FY2008 · net margin -33.2% → 31.4%

MarginsNet marginFCF margin

FY2025: net 31.4% · free cash flow 28.4% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $4.98B operating cash − $898.4M capex = $4.08B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -17% (FY2009) → 14% (FY2025) · on assets 11.1%

Balance sheetLiabilitiesEquity

FY2025: $40.56B assets · $9.30B liabilities · $31.26B equity

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014
Revenue	14,343	14,202	13,117	12,173	16,072	8,497	6,558	5,146	5,872	4,860	4,104	2,820
Net income	4,505	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636	338
Diluted EPS	41.48	38.34	34.77	38.22	71.97	30.52	18.46	21.29	10.34	7.70	5.52	2.98
Diluted shares	109	115	114	114	112	115	115	115	116	116	115	113
Operating cash flow	4,979	4,421	4,594	5,015	7,081	2,618	2,430	2,195	1,307	1,486	1,331	752
Capital expenditures	898	756	719	590	552	615	430	383	273	512	678	333
Free cash flow	4,081	3,665	3,875	4,425	6,529	2,004	2,000	1,812	1,035	974	653	419
Cash & equivalents	3,118	2,488	2,730	3,106	2,886	2,194	1,618	1,468	813	535	809	649
Total assets	40,559	37,759	33,080	29,215	25,435	17,163	14,805	11,735	8,764	6,973	5,609	3,838
Total liabilities	9,302	8,406	7,107	6,551	6,666	6,138	3,716	2,977	2,620	2,524	1,954	1,287
Shareholders' equity	31,257	29,354	25,973	22,664	18,769	11,025	11,090	8,757	6,144	4,449	3,655	2,550

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. See methodology.